The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Fulvestrant Plus Palbociclib in Breast Cancer

​Joanne Blum, MD, PhD, FACP
Published Online: 12:28 AM, Fri June 17, 2016

Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the combination of fulvestrant and palbociclib (Ibrance) in patients with breast cancer, as well as the synergy fulvestrant has with other CDK4/6 inhibitors.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.